Anika Therapeutics (NSDQ:ANIK) touted data today from a study evaluating the use of its Hyalofast biodegradable, hyaluronic acid-based scaffold in combination with autologous adult mesenchymal stem cell therapy for cartilage lesions in the knee.
The study, which was published in Knee Surgery Sports Traumatology Arthroscopy, showed that the treatment was equally effective among patients, regardless of age.
Get the full story at our sister site, Drug Delivery Business News.